Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 172.00M | 167.82M | 164.50M | 156.24M | 155.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 172.00M | 167.82M | 164.50M | 156.24M | 155.55M |
| Cost of Revenue | 94.74M | 92.94M | 92.01M | 90.77M | 87.96M |
| Gross Profit | 77.26M | 74.88M | 72.49M | 65.47M | 67.59M |
| SG&A Expenses | 85.19M | 81.27M | 85.01M | 86.02M | 77.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.90M | 181.90M | 184.90M | 184.41M | 172.71M |
| Operating Income | -15.90M | -14.08M | -20.40M | -28.17M | -17.16M |
| Income Before Tax | -16.13M | -17.85M | -19.02M | -27.68M | -15.29M |
| Income Tax Expenses | -804.00K | -150.00K | -375.00K | -620.00K | -960.00K |
| Earnings from Continuing Operations | -15.32M | -17.70M | -18.64M | -27.06M | -14.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.32M | -17.70M | -18.64M | -27.06M | -14.33M |
| EBIT | -15.90M | -14.08M | -20.40M | -28.17M | -17.16M |
| EBITDA | 2.29M | 3.91M | -2.29M | -9.90M | 1.20M |
| EPS Basic | -0.12 | -0.14 | -0.15 | -0.21 | -0.11 |
| Normalized Basic EPS | -0.07 | -0.05 | -0.09 | -0.13 | -0.07 |
| EPS Diluted | -0.12 | -0.14 | -0.15 | -0.21 | -0.11 |
| Normalized Diluted EPS | -0.07 | -0.05 | -0.09 | -0.13 | -0.07 |
| Average Basic Shares Outstanding | 127.16M | 126.95M | 126.41M | 126.11M | 125.93M |
| Average Diluted Shares Outstanding | 127.16M | 126.95M | 126.41M | 126.11M | 125.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
